Heart Failure
Top in cardiology: AI tool for predicting CVD risk; unregulated heart failure therapies
A deep-learning model may help physicians predict atherosclerotic CVD risk in patients, according to data presented at the Radiological Society of North America annual meeting.
‘Unprecedented pace’ of extreme temperatures associated with death from common CV conditions
A multinational data set across climate zones suggests an association between extreme hot and cold temperatures and CV cause-specific mortality, with the largest excess deaths associated with HF, researchers reported.
Data suggest ‘crystal-clear class effect’ for SGLT2 inhibitor benefits in HF
An analysis of 13 randomized controlled trials of SGLT2 inhibitors showed the class reduced CV death, HF hospitalization and serious adverse events in people with HF, according to data published in The American Journal of Cardiology.
Alternative HF therapies could worsen symptoms, interact with prescribed medications
Complementary and alternative therapies for HF could potentially worsen symptoms and interact with prescribed medications, and clinicians and patients should be aware of a lack of federal regulation for such therapies, researchers wrote.
‘No time to waste’: Implement guideline-recommended HF therapies simultaneously
The benefits of HF medications are additive and incremental and provide similar benefits to patients with ischemic and nonischemic etiologies when initiated simultaneously, according to a speaker.
Amid pandemic, elective CVD admissions down, ED visits up in UK
In the U.K., the severity of CVD comorbidities increased during the pandemic while elective admissions and procedures decreased, an observation accompanied by increased emergency admissions, researchers reported.
Long-term salt preferences may influence CVD risk
Less use of added dietary salt is associated with lower risk for CVD, particularly HF and ischemic heart disease, whether or not individuals follow the Dietary Approaches to Stop Hypertension diet, data from a prospective study show.
Empagliflozin efficacy, safety similar in Black, white patients with HF
The safety and efficacy of empagliflozin to treat HF was similar in Black and white patients, despite Black patients being at higher risk for HF, researchers reported.
Nonsteroidal MRAs: Will finerenone take the throne?
Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial outcomes in several renin-angiotensin-aldosterone system-mediated disease states.
No cardiac remodeling with empagliflozin in people without diabetes, significant HF
CHICAGO — In people without diabetes or significant HF, 6 months of empagliflozin treatment was not associated with any meaningful changes in cardiac remodeling indices compared with placebo, according to data from the EMPA-HEART 2 study.